Pannexin 1 crosstalk with the Hippo pathway in malignant melanoma
The FEBS Journal · 2025
DOI: 10.1111/febs.17396 ↗Kurz gefasst
Fachartikel in der Zeitschrift The FEBS Journal, 2025. Verfasst von Samar Sayedyahossein und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, National Institutes of Health, Bethesda, MD, USA. Hauptthemen laut MEDLINE: Melanoma, Nerve Tissue Proteins, Connexins, Protein Serine-Threonine Kinases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural NIH HHS, CIHR, Canadian Institutes of Health Research.
Abstract (Originalsprache)
In this study, we explored the intricate relationship between Pannexin 1 (PANX1) and the Hippo signaling pathway effector, Yes‐associated protein (YAP). Analysis of The Cancer Genome Atlas (TCGA) data revealed a significant positive correlation between PANX1 mRNA and core Hippo components, Yes‐associated protein 1 [YAP], Transcriptional coactivator with PDZ‐binding motif [TAZ], and Hippo scaffold, Ras GTPase‐activating‐like protein IQGAP1 [IQGAP1], in invasive cutaneous melanoma and breast carcinoma. Furthermore, we demonstrated that PANX1 expression is upregulated in invasive melanoma cell lines and is associated with increased YAP protein levels. Notably, our investigations uncovered a previously unrecognized interaction between endogenous PANX1 and the Hippo scaffold protein IQGAP1 in melanoma cells. Moreover, our findings revealed that IQGAP1 exhibits differential expression in melanoma cells and plays a regulatory role in cellular morphology. Functional studies involving PANX1 knockdown provided compelling evidence that PANX1 modulates YAP protein levels and its cotranscriptional activity in melanoma and breast carcinoma cells. Importantly, our study highlights the potential therapeutic significance of targeting PANX1. Pharmacological inhibition of PANX1 using selective FDA‐approved inhibitors or PANX1 knockdown reduced YAP levels in melanoma cells. Furthermore, our Clariom™ S analysis unveiled key genes implicated in cell proliferation, such as neuroglin1 (NRG1), β‐galactoside binding protein and galectin‐3 (LGALS3), that are affected in PANX1‐deficient cells. In summary, our investigation delves into the intricate interplay between PANX1 and YAP in the context of invasive melanoma, offering valuable insights into potential therapeutic strategies for effective treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine, National Institutes of Health, Bethesda, MD, USA.
- Department of Anatomy and Cell Biology, Schulich School of Medicine and Dentistry, The University of Western Ontario, London, Canada.
- Department of Mathematics, Illinois State University, Normal, IL, USA.
- Ontario College of Pharmacists, Toronto, Canada.
- Department of Physiology and Pharmacology, Schulich School of Medicine and Dentistry, The University of Western Ontario, London, Canada.
ORCID-Profile: Silvia Penuela
Förderung
- Intramural NIH HHS
- CIHR
- Canadian Institutes of Health Research
Zitieren
APA
Sayedyahossein, S., Huang, K., Zhang, C., Karimi, M., Bahmani, M., O'Donnell, B. L., Wakefield, B., Li, Z., Johnston, D., Leighton, S. E., Huver, M. S., Dagnino, L., Sacks, D. B., & Penuela, S. (2025). Pannexin 1 crosstalk with the Hippo pathway in malignant melanoma. The FEBS Journal. https://doi.org/10.1111/febs.17396
Vancouver
Sayedyahossein S, Huang K, Zhang C, Karimi M, Bahmani M, O'Donnell BL, et al. Pannexin 1 crosstalk with the Hippo pathway in malignant melanoma. The FEBS Journal. 2025. doi:10.1111/febs.17396
BibTeX
@article{Sayedyahossein2025,
author = {Sayedyahossein, Samar and Huang, Kenneth and Zhang, Christopher and Karimi, Mehdi and Bahmani, Mehrnoosh and O'Donnell, Brooke L and Wakefield, Brent and Li, Zhigang and Johnston, Danielle and Leighton, Stephanie E and Huver, Matthew S and Dagnino, Lina and Sacks, David B and Penuela, Silvia},
title = {Pannexin 1 crosstalk with the Hippo pathway in malignant melanoma},
journal = {The FEBS Journal},
year = {2025},
doi = {10.1111/febs.17396}
}
EUVIMED